MDS Clinical Trials

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
N
Allogeneic Hematopoietic Stem Cell Transplant for GATA2 Mutations
Recruiting
  • GATA2
  • +2 more
  • Allogeneic HSCT
  • +8 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center, 9000 Rockville Pi
2022-04-07
Apr 7, 2022
M
Metabolically Optimized, Non-cytotoxic Low Dose Weekly Decitabine/Venetoclax in MDS and AML
Recruiting
  • MDS
  • AML
  • Bronx, New York
    Montefiore Medical Center
2022-03-24
Mar 24, 2022
D
GvHD Prophylaxis in Unrelated Donor HCT: Randomized Trial Comparing PTCY Versus ATG
Recruiting
  • Graft Vs Host Disease
  • +5 more
  • Augsburg, Germany
  • +15 more
2022-03-21
Mar 21, 2022
M
A Phase II Study of Vibecotamab (XmAb14045) for MRD- Positive AML and MDS After Hypomethylating Agent Failure
Not yet recruiting
  • AML
  • MDS
  • Houston, Texas
    M D Anderson Cancer Center
2022-03-08
Mar 8, 2022
G
Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Myelodysplastic Syndrome Low Risk
Active, not recruiting
  • MDS
  • transplantation
  • Amiens, France
  • +36 more
2022-03-09
Mar 9, 2022
G
Venetoclax in Patients With MDS or AML in Relapse After AHSCT
Not yet recruiting
  • MDS
  • AML
  • venetoclax + azacitidine +/- donor lymphocyte infusion
  • Amiens, France
  • +13 more
2022-03-09
Mar 9, 2022
J
A Safety and Efficacy Study of SHR-1702 Monotherapy in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
Active, not recruiting
  • AML
  • MDS
  • Tianjin, Tianjin, China
    Blood disease hospital of Chinese Academy of Medical Sciences
2022-03-07
Mar 7, 2022
B
Phase 2, Open-Label, Single Arm Study, With BST-236 in Adults With R/R AML or Higher-Risk MDS
Recruiting
  • AML, Adult
  • +3 more
  • Shreveport, Louisiana
  • +3 more
2022-02-02
Feb 2, 2022
D
Safety and Efficacy of Allogeneic NK Cell Infusions in Patients With Relapsed/Refractory AML and High Risk MDS
Recruiting
  • AML, Adult Recurrent
  • MDS
  • DVX201
  • Durham, North Carolina
    Duke University Hospital
2022-02-11
Feb 11, 2022
A
A Study of APG-115 Alone or Combined With Azacitidine in Patients With AML, CMML, or MDS
Recruiting
  • AML
  • +6 more
  • Gilbert, Arizona
  • +6 more
2022-02-08
Feb 8, 2022
A
Study of APVO436 in Patients With AML or MDS
Recruiting
  • AML
  • MDS
  • APVO436
  • San Francisco, California
  • +11 more
2022-02-08
Feb 8, 2022
Y
CPX-351 in Patients Treated for Higher-risk Myelodysplastic Syndromes Experiencing Hypomethylating Agent Failure. - 2021
Withdrawn
  • MDS
  • New Haven, Connecticut
    Yale University; Smilow Cancer Center
2022-01-06
Jan 6, 2022
N
NKX101, Intravenous Allogeneic Engineered Natural Killer Cells, in Adults With AML or MDS
Recruiting
  • Relapsed/Refractory AML
  • +3 more
  • NKX101 - CAR NK cell therapy
  • Denver, Colorado
  • +6 more
2022-01-19
Jan 19, 2022
A
APR-548 in Combination With Azacitidine for the Treatment of TP53 Myelodysplastic Syndromes (MDS)
Recruiting
  • MDS
  • Myelodysplastic Syndromes
  • APR-548 + Azacitidine
  • Tampa, Florida
  • +3 more
2022-01-18
Jan 18, 2022
I
National Longitudinal Cohort of Hematological Diseases
Recruiting
  • Multiple Myeloma
  • +17 more
    • Tianjin, Tianjin, China
      Institute of Hematology & Blood Diseases Hospital
    2022-01-11
    Jan 11, 2022
    A
    Frailty Phenotype Assessments to Optimize Treatment Strategies for Older Patients With Hematologic Malignancies
    Recruiting
    • Leukemia, Acute
    • MDS
    • Bone Marrow or Peripheral Blood Graft (BMT)
    • +2 more
    • Philadelphia, Pennsylvania
      Abramson Cancer Center of the University of Pennsylvania
    2022-01-07
    Jan 7, 2022
    G
    Study Evaluating Combination of Luspatercept in LR-MDS Without RS Having Failed or Being Ineligible to ESA
    Not yet recruiting
    • MDS
    • Myelodysplastic Syndromes
    • Luspatercept Injection [Reblozyl]
    • Eprex
    • Amiens, France
    • +28 more
    2021-12-20
    Dec 20, 2021
    H
    Fedratinib in Myelodysplastic /Myeloproliferative Neoplasms (MDS/MPNs) and Chronic Neutrophilic Leukemia (CNL)
    Recruiting
    • Myeloproliferative Neoplasm
    • +2 more
    • Fedratinib Pill
    • Tampa, Florida
      Moffitt Cancer Center
    2021-12-15
    Dec 15, 2021
    T
    Aza With or Without ATRA in Newly Diagnosed Unfit AML or Intermediate,High or Very High Risk MDS
    Recruiting
    • AML
    • +3 more
    • Suzhou, Jiangsu, China
      The First Affiliated Hospital of Soochow University
    2021-12-27
    Dec 27, 2021
    J
    Pevonedistat and Low Dose Cytarabine in Adult Patients With AML and MDS - 2021
    Completed
    • Acute Myelogenous Leukemia
    • +3 more
    • Miami, Florida
      University of Miami
    2021-12-07
    Dec 7, 2021
    A
    Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 397 in Subjects With Selected Relapsed or Refractory Hematological Malignancies - 2019
    Terminated
    • Multiple Myeloma
    • +6 more
    • AMG 397
    • +2 more
    • Birmingham, Alabama
    • +20 more
    2021-12-20
    Dec 20, 2021
    T
    Improving Cognitive Function in Older Adults Undergoing Stem Cell Transplant
    Recruiting
    • Leukemia
    • +4 more
    • CHAMPS-II adapted to adults 60+ years in HCT setting
    • Survivorship education active control
    • Omaha, Nebraska
      University of Nebraska Medical Center
    2021-11-26
    Nov 26, 2021
    G
    ASTX727 and Donor Lymphocyte Infusions After Allogenic Stem Cell Transplantation in Very High Risk MDS or AML Patients
    Recruiting
    • MDS
    • AML
    • Angers, France
    • +13 more
    2021-11-17
    Nov 17, 2021
    G
    Randomized Phase III Study of Decitabine +/- Hydroxyurea (HY) Versus HY in Advanced Proliferative CMML - 2021
    Completed
    • MDS
    • Saint-Denis, La Réunion, France
    • +44 more
    2021-11-17
    Nov 17, 2021
    M
    Allo vs Hypomethylating/Best Supportive Care in MDS (BMTCTN1102)
    Active, not recruiting
    • MDS
    • Allogeneic Hematopoietic Cell Transplant
    • Hypomethylating Therapy / Best Supportive Care
    • Duarte, California
    • +36 more
    2021-11-02
    Nov 2, 2021